Analysis of FMC Corporation’s Q3 2026 10-Q
Filing dated 30 October 2026 for the quarter ended 30 September 2026
Where the filing and the story diverge
FMC’s Q3 revenue fell to $105.9M after $639M of charges to reset its North American pricing and reprice stock held by customers, and the quarter’s $2.07B net loss turned shareholders’ equity negative. The balance sheet now rests on three things: a leverage covenant at 6.1x against a 6.75x limit that returns on 31 December, $811.9M of rebates owed to customers while their prepayments have nearly disappeared, and asset sales and a 2027 recovery that management says are on track.
- Three findings: Shareholders’ equity turned negative after a $2.07B quarterly loss; Leverage at 6.1x against a 6.75x covenant that returns on 31 December; Rebates owed nearly doubled while customer prepayments almost disappeared. Each is set out below with the figure, where it sits in the filing and what would close it.
- On the calls. 0 of 3 findings were sidestepped or never asked.
- What it does not show. Nothing here shows a misstatement or a covenant breach.
- Q3 revenue
- $105.9M vs $542.2M
- Net loss attributable to FMC
- $(2,066.9)M
- Adjusted EBITDA
- $(558.6)M
- Total debt
- $4,177.7M
- Cash
- $735.8M
Area by area: what is solid and what is stretched
FMC has revolver room and largely fixed-rate debt. The risk sits in covenant headroom, negative equity, and cash collection while customers hold minimal inventory and stop prepaying.
Three findings, ranked by importance
Each is set out in full below: what the filing shows, the numbers, the evidence and what would close it.
Shareholders’ equity turned negative after a $2.07B quarterly loss
Equity fell from $3,773.8M a year earlier to negative $19.4M. Retained earnings dropped to $1,398.8M from $4,170.1M in nine months.
Most of the $2,066.9M Q3 net loss attributable to FMC was non-cash: $808.8M of valuation allowances on deferred tax assets (Switzerland $491M, US $317M) and a $287.5M impairment of indefinite-lived intangibles tied to Rynaxypyr. The filing says the tax charge was taken because the company has limited ability to rely on future earnings forecasts in those entities. If the 2027 and 2028 recovery arrives, parts of the allowance can reverse into earnings, but that is conditional. On top of the non-cash items sit the $672M of commercial-action charges against adjusted EBITDA.
Income statement, equity statement and Note 16 of the 10-Q; the results release for the special items.
Leverage at 6.1x against a 6.75x covenant that returns on 31 December
Management said total leverage would have been 6.1x against the 6.75x limit that comes back at year end, with interest coverage of 2.3x against a 2.0x floor. The limit holds through 2027, then steps down to 3.75x by Q1 2029.
Covenant EBITDA is defined differently from reported adjusted EBITDA and lets FMC add back charges like this quarter’s commercial actions, which is why leverage looks far better on the covenant measure than on the reported one. Management said it expects to remain in compliance at year end and through 2027. Year-end compliance depends on three things: the India sale closing on 1 December, a Delaware sale-leaseback closing by year end, and Q4 customer prepayments matching 2025. Further out, management’s ~$3.1B year-end net debt against 2028 EBITDA guidance of $760M to $840M implies roughly 3.7x to 4.1x (our calculation, indicative only), close to the 3.75x step-down.
Notes 9 and 10 of the 10-Q for the covenant terms; the earnings call for the September ratios.
Rebates owed nearly doubled while customer prepayments almost disappeared
Accrued rebates rose by $394.5M in nine months, where most of the $500M North American charge landed. Advance payments from customers fell to $67.8M from $453.1M.
Management describes the $500M North American charge as non-cash and, over the crop cycle, cash-neutral: lower collections in Q4 2026 offset by lower rebate payouts in Q4 2027. The separate $175M repricing of high-priced stock held by customers does reduce future cash, through credit notes and pricing credits, over four to six quarters. The full-year free cash flow guide of negative $350M to negative $150M assumes customer prepayments repeat at 2025 levels, which the September balance makes the single most important assumption for Q4.
Balance sheet in the 10-Q; the earnings call for the cash mechanics.
Other findings, checked and set aside
Each item was tested against the filing. None changes the lead findings above.
| Item | What the filing shows, and why it is not a lead finding |
|---|---|
| XBRL: new tags for the commercial actions | FMC created custom tags for the revenue charge and the related adjustments, plus a covenant-period axis, so the October actions are traceable in the data itself. |
| CFO cash remark, reconciled | On the call, cash “increased $259 million”; the cash flow statement shows +$151.3M for the year to date. The Q2 10-Q shows $476.6M at June, so the $259M is the quarter-on-quarter rise. Both are right on their own basis. |
| Receivable sales | $134.4M of receivables sold through securitisation; third-party factoring fell to $85.0M from $206.2M. |
| Project Foundation | $700M to $775M of lifetime restructuring charges for a $200M run-rate savings target by end-2027. |
| Dividend | Cut to $0.08 a quarter from $0.58 in October 2025; nine-month dividends paid fell to $30.4M from $218.4M. |
| Pakistan joint venture | The remaining 40% was bought for $8.6M. |
What management said about each finding
The CFO explained the write-downs in prepared remarks: "We recorded non-cash adjustments of approximately $809 million to deferred tax assets in the United States and Switzerland, as well as a non-cash impairment charge against our indefinite-lived intangible assets related to our Rynaxypyr business of $288 million." Neither management nor analysts mentioned that shareholders’ equity had turned negative.
The CFO gave the ratios unprompted: total debt to covenant EBITDA "would have been 6.1x as compared to the 6.75x covenant limit that will be reinstated at December 31, 2026", and said "we expect to remain in compliance with all covenants at year-end." No analyst asked what Q4 EBITDA the test needs, or what happens if India or Delaware slips.
Asked about prepayments, the CFO said: "Our free cash flow guidance for 2026 assumes flat prepays to the prior year." On the $175M repricing: "So over a 4- to 6-quarter period, that probably is a cash headwind for the company." The fall in prepayments already on the balance sheet was not discussed.
9 disclosures moved
10-Q Q3 2026 compared with the 10-K for 31 December 2025.
| Status | Disclosure | Before | Now |
|---|---|---|---|
| Changed | Accrued customer rebates Balance sheet | $417.4M | $811.9M |
| Changed | Advance payments from customers Balance sheet | $453.1M | $67.8M |
| Changed | Total FMC stockholders’ equity Q3 2026 vs Q3 2025 · results release | $3,773.8M | $(19.4)M |
| New | 8.0% senior secured notes due 2031 Note 10 | None | $1,200.0M, refinancing the October 2026 maturity |
| Changed | Supply chain finance obligations Note 18 | $109.5M | $213.1M |
| New | Tessenderlo Group shareholding Note 13 | None | About 20% for $403M, with a board seat |
| New | India business held for sale Note 3 | Operating | $282.6M net assets; $252M sale, closing 1 December |
| New | Revenue charge for commercial pricing actions Income statement; new XBRL tag | Not present | $(639)M in Q3 |
| Changed | Share buybacks Note 13 | Authorised | Frozen to 31 December 2028; $825M authorisation unused |
A pricing-model reset, negative equity, new secured debt, a 20% strategic shareholder and assets held for sale reshaped FMC’s balance sheet in nine months.
5 markers for 31 December
Set before the numbers, so the read can be checked afterwards.
| Marker | Now | Gap widens if | Gap closes if | Result |
|---|---|---|---|---|
| Leverage covenant at 31 December | 6.1x at 30 September against a 6.75x limit | The test is failed, waived or amended again | Passed with headroom | Awaiting |
| Q4 customer prepayments | Advance payments $67.8M at September; guide assumes 2025 levels | Prepayments come in below 2025 | Prepayments match or beat 2025 | Awaiting |
| Full-year free cash flow | Guided at $(350)M to $(150)M | Below the guided range | Within or above the range | Awaiting |
| Accrued customer rebates | $811.9M, up 94% in nine months | The balance does not fall after the year-end payout | It falls as rebates are paid under the new model | Awaiting |
| India sale and Delaware sale-leaseback | India due 1 December; Delaware by year end | Either slips past year end | Both close on schedule | Awaiting |
These are monitoring checks set before the numbers, not forecasts of a loss or breach.
6 questions, checked against the call
Raised by the 10-Q. To be tested again at Leverage covenant test on 31 December.
What this does and does not show
Supplier finance doubled as payables shrank
Supply chain finance obligations rose to $213.1M from $109.5M, about 29% of $723.9M trade payables; excluding them, underlying payables fell about $150.7M.
Not raised on the call.
What would resolve this: The programme stops growing as a share of payables.
A bigger reserve on a smaller receivables book
The receivables allowance doubled to $87.6M, 4.8% of gross receivables against 2.1%, and $92.6M of Latin American receivables were written off this year.
Not raised on the call.
What would resolve this: Write-offs stop and the allowance stabilises.
Free cash flow includes a $200M upfront payment
Corteva paid $200.0M in June for a decade of rimisoxafen supply; without it, nine-month free cash flow of $(288.9)M would have been about $(488.9)M (our calculation).
Not raised on the call.
What would resolve this: Underlying cash generation improves without one-off receipts.
Nothing here shows a misstatement or a covenant breach.
Management expects to stay in compliance, most of the Q3 loss is non-cash, and the debt is largely fixed-rate with revolver room.
- The 31 December covenant test passes with headroom
- Q4 prepayments match 2025
- India and Delaware close on time
- Rebates fall as the new model takes over
- Another covenant amendment or waiver
- Prepayments come in well below 2025
- Free cash flow misses the guide
- Further impairments or receivable write-offs
Every figure ties back to the filing
| FMC Form 10-Q, quarter ended 30 September 2026 | Open ↗ |
| Q3 2026 results release (Exhibit 99.1), 29 October 2026 | Open ↗ |
| Q3 2026 earnings call, 30 October 2026 | Third-party transcripts |
| FMC Form 10-Q, quarter ended 30 June 2026 (cash reconciliation) | Filed with the SEC |
Helmledgers reads the full filing, including the notes, and ties every figure to the statement or note it comes from, with each number re-checked against the source before release. This is an accounting read of public SEC filings, not an audit opinion and not investment advice.
- Severity
- High: material effect on cash, debt or reported results. Medium: worth tracking, smaller or less certain effect.
- On the call
- Direct answer, Partly answered (topic addressed, figure missing), Sidestepped (raised but not answered) or Not asked.
- Since the read
- Confirmed by a later disclosure, Escalated (grown since), Open (untested) or Missed (not flagged by the read).
- Said versus done
- Kept, Slipped (late), Changed (plan or terms changed), Missed or Reversed.
- Markers
- Measurable checks set before results, each with what would widen or close the gap. Scored after the next results.
- Closes if
- The evidence that would resolve a finding.
Helmledgers and its analysts hold no position in FMC securities.
This is an accounting read of public SEC filings. It is not an audit opinion and not investment advice.